Text Size
1 study found for:    NCT01286987

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Conditions: Advanced or Recurrent Solid Tumors;   Breast Neoplasms;   Ovarian Cancer, Epithelial;   Ewing Sarcoma;   Small Cell Lung Carcinoma;   Prostate Cancer;   Pancreas Cancer
Intervention: Drug: BMN 673
To Top

† Indicates status has not been verified in more than two years